canada clinical guidance

Anxiety & panic disorder

A Canadian clinical summary of anxiety & panic disorder, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian anxiety CPG

Source-attributed clinical priorities

  • Confirm the anxiety presentation while excluding urgent medical mimics, substance effects and co-occurring depression or suicide risk.
  • Offer evidence-based psychological treatment and, when indicated, first-line pharmacotherapy chosen for the specific disorder and patient context.
  • Avoid routine long-term benzodiazepine treatment; monitor response, function, adverse effects and relapse risk.
  • Distinguish panic attacks occurring within another disorder from panic disorder and from cardiopulmonary or endocrine illness.
sources for this section:Canadian anxiety CPG

Practical assessment and management workflow

1
Map triggers, avoidance, anticipatory anxiety, physical symptoms and impairment across home, work and relationships.
2
Review caffeine, cannabis, stimulants, alcohol withdrawal, thyroid symptoms and medicines that can provoke anxiety.
3
Offer disorder-specific cognitive behavioural treatment and explain the expected early course of any medication trial.
4
Track avoidance and function as well as symptom scores, and build a relapse plan after sustained improvement.
sources for this section:Canadian anxiety CPG

Safety, red flags and urgent escalation

  • Assess urgently when chest pain, syncope, severe dyspnea, intoxication or a new neurologic presentation suggests a medical emergency.
  • Ask about suicide risk and severe depression even when anxiety is the presenting complaint.
  • Warn that benzodiazepines impair driving, combine dangerously with opioids or alcohol and can cause dependence.
sources for this section:Canadian anxiety CPG

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian anxiety CPG

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian anxiety CPG

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Anxiety Disorders Association of CanadaCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.